In Vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital invasive fungal surveillance net (CHIF-NET) study

Journal of Clinical Microbiology

Volumn 50, Issue 12, 2012, Pages 3952-3959

  Wang, He ^a   Xiao, Meng ^a,b   Chen, Sharon C A ^c   Kong, Fanrong ^c   Sun, Zi Yong ^d   Liao, Kang ^e   Lu, Juan ^f   Shao, Hai Feng ^g   Yan, Yan ^h   Fan, Hong ⁱ   Hu, Zhi Dong ^j   Chu, Yun Zhuo ^k   Hu, Tie Shi ^l   Ni, Yu Xing ^m   Zou, Gui Ling ^f   Xu, Ying Chun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^c WESTMEAD HOSPITAL   (Australia)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f HARBIN MEDICAL UNIVERSITY   (China)

^g NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^h PEKING UNIVERSITY FIRST HOSPITAL   (China)

ⁱ SICHUAN UNIVERSITY   (China)

^j TIANJIN MEDICAL UNIVERSITY   (China)

^k CHINA MEDICAL UNIVERSITY   (China)

^l People's Hospital of Liaoning Province   (China)

^m SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA QUERCITRUSA; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FUNGAL STRAIN; FUNGUS ISOLATION; GEOGRAPHIC DISTRIBUTION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; NONHUMAN; PICHIA ANOMALA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPECIES IDENTIFICATION; TRICHOSPORON;

ANTIFUNGAL AGENTS; CHINA; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; EPIDEMIOLOGICAL MONITORING; FLUCONAZOLE; HUMANS; MYCOSES; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES; YEASTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA QUERCITRUSA; CANDIDA TROPICALIS; FILOBASIDIELLA NEOFORMANS;

EID: 84869233276     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01130-12     Document Type: Article

References (42)

1. Arendrup MC, et al. 2008. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487-494. (Pubitemid 351513938)
2. Arendrup MC, et al. 2011. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J. Clin. Microbiol. 49:3300-3308.
3. Arnold HM, et al. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368.
4. Borman AM, et al. 2008. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J. Clin. Microbiol. 46:933-938. (Pubitemid 351379982)
5. Chen S, et al. 2006. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12:1508-1516. (Pubitemid 44570891)
6. Chou HH, Lo HJ, Chen KW, Liao MH, Li SY. 2007. Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. Diagn. Microbiol. Infect. Dis. 58:427-433.
7. Clinical and Laboratory Standards Institute. 2009. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline, 2nd ed, M44-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2009. Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts; informational supplement, 3rd ed, M44-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Colombo AL, et al. 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol. 44:2816-2823. (Pubitemid 44228575)
10. Cuenca-Estrella M, et al. 2011. Prevalence of Candida bracarensis and Candida nivariensis in a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia. Med. Mycol. 49:525-529.
11. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
12. Falagas ME, Apostolou KE, Pappas VD. 2006. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur. J. Clin. Microbiol. Infect. Dis. 25:419-425. (Pubitemid 44078593)
13. Garey KW, et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31. (Pubitemid 43939072)
14. Guo LN, et al. 2011. Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China. J. Clin. Microbiol. 49:3805-3811.
15. Hajjeh RA, et al. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527. (Pubitemid 38500790)
16. Hautala T, et al. 2007. A cluster of Candida krusei infections in a haematological unit. BMC Infect. Dis. 7:97. doi:10.1186/1471-2334-7-97.
17. Horn DL, et al. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48:1695-1703.
18. Jang SJ, et al. 2005. PFGE-based epidemiological study of an outbreak of Candida tropicalis candiduria: the importance of medical waste as a reservoir of nosocomial infection. Jpn. J. Infect. Dis. 58:263-267.
19. Leaw SN, et al. 2006. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J. Clin. Microbiol. 44:693-699.
20. Li C-R, Peng S-H, Li D, Li Y. 2002. A hospital acquired infection of deep fungus: a clinical investigation and drug resistance. Chin. J. Nosocomiol. 12:485-487.
21. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. 2008. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46:2659-2664.
22. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. 2008. Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J. Clin. Microbiol. 46:374-376.
23. Miceli MH, Diaz JA, Lee SA. 2011. Emerging opportunistic yeast infections. Lancet Infect. Dis. 11:142-151.
24. Mirhendi H, et al. 2011. Differentiation of Candida glabrata, C. nivariensis and C. bracarensis based on fragment length polymorphism of ITS1 and ITS2 and restriction fragment length polymorphism of ITS and D1/D2 regions in rDNA. Eur. J. Clin. Microbiol. Infect. Dis. 30:1409-1416.
25. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
26. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618. (Pubitemid 47299877)
27. Pfaller MA, et al. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 70:330-343.
28. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
29. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
30. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. (Pubitemid 46167771)
31. Pfaller MA, et al. 2009. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 47:117-123.
32. Pfaller MA, et al. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48:1366-1377.
33. Pfaller MA, et al. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745. (Pubitemid 46933900)
34. Pfaller MA, et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
35. Pfaller MA, Diekema DJ, Sheehan DJ. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
36. Pfaller MA, et al. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43:2163-2167. (Pubitemid 40656221)
37. Sabino R, et al. 2010. Epidemiology of candidemia in oncology patients: a 6-year survey in a Portuguese central hospital. Med. Mycol. 48:346-354.
38. Sandven P, et al. 2006. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44:1977-1981. (Pubitemid 43902142)
39. Sofair AN, et al. 2006. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin. Infect. Dis. 43:32-39. (Pubitemid 43939073)
40. Trofa D, Gacser A, Nosanchuk JD. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21:606-625.
41. Xu X-L, Yang P-H, Sun Y-Q, Fan X. 2007. Deep fungi infection: flora distribution and drug resistance. Chin. J. Nosocomiol. 17:349-351.
42. Zilberberg MD, Shorr AF, Kollef MH. 2008. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect. Control Hosp. Epidemiol. 29:978-980.